<DOC>
	<DOC>NCT02418481</DOC>
	<brief_summary>In this study, effects of γδT cells on human breast cancer (her2-, er-,pr-) in combination with tumor reducing surgery, for example cryosurgery going to be investigated.</brief_summary>
	<brief_title>Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)</brief_title>
	<detailed_description>Breast tumor will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as immunotherapy.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1. Age:1875 2. Karnofsky performance status &gt;50 3. Diagnosis with breast tumors based on histology or the current accepted radiological measures. 4. Classification tumor,nodes,metastasisclassification(TNM) stage: Ⅱ,Ⅲ,Ⅳ 5. Will receive cryosurgery, gd Tcells/ DCCIK. 6. Life expectancy: Greater than 3 months 7. Ability to understand the study protocol and a willingness to sign a written informed consent document 1. Patients with other kinds of cancer 2. History of coagulation disorders or anemia 3. Patients with heart disease and diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>γδ T Cell</keyword>
	<keyword>breast cancer</keyword>
	<keyword>her2-</keyword>
	<keyword>er-</keyword>
	<keyword>pr-</keyword>
</DOC>